Skip to main content
APPLY

GLP-1

Why GLP-1 Results in Real Life Differ From Clinical Trials

Trial design, participant selection, treatment persistence and missing data all affect the distance between published trial averages and real-world cohorts.

Why the distinction matters

Two questions are routinely merged. One asks what a treatment can do under controlled trial conditions in a selected population. The other asks what tends to happen across ordinary care, where selection, follow-up and data completeness are all different. Merging them makes any comparison look like a verdict.

Two different questions

Efficacy versus effectiveness

Trial efficacy describes results under defined trial conditions in a selected population. Real-world effectiveness describes results observed across ordinary care. The two are measured differently and answer different questions.

  • Trial efficacyDefined conditions

    A selected population, defined eligibility, protocol-driven follow-up and structured data collection.

  • Real-world effectivenessOrdinary care

    Unselected populations, variable follow-up, variable monitoring and incomplete data.

What separates the two

  • Population: trial eligibility criteria select who is studied; ordinary care does not.
  • Follow-up: trial follow-up is defined and protocol-driven; real-world follow-up varies.
  • Persistence: how long people remain on treatment differs between settings.
  • Missing data: incomplete records change what a cohort average can represent.

Persistence belongs on that list, but it does not explain the whole distance. Attributing the entire gap to whether people kept taking a medication ignores selection, follow-up and data completeness — all of which move an average without anyone's behaviour changing.

What this can support

  • Reading a published average together with the setting that produced it.
  • Asking which question a quoted number is answering.
  • Treating a trial-to-real-world difference as a structural question, not a verdict.

What it cannot support

  • Generating a personal forecast.
  • Claiming the drug failed.
  • Claiming the entire difference was caused by behaviour.
  • Recommending a medication or protocol.

Questions to take to a licensed clinician

  1. 01Is this figure from a trial population or from routine care?
  2. 02How long were people followed, and how many were still being measured at the end?
  3. 03What would we track, and how would we know whether it was working?

The free guide explains how the system approaches decisions like these — measurement first, structure before intensity, ownership at the end.

Get the Ascendant Goodies

Sources

Sources last checked

Written by

AbtinFounder, Ascendant Health

The position

GLP-1 medications can be effective. The difference between trial outcomes and everyday outcomes often exposes an execution and adherence problem.

GLP-1 outcomes

Related reading

GLP-1Trial Results Are Not Personal Forecasts: Reading STEP 1 CorrectlyGLP-1What Happens After GLP-1 Treatment Stops?GLP-1Weight Loss and Lean Mass: What Body-Composition Research Actually Shows

This article is general education. It is not medical advice, a diagnosis or treatment guidance, and it does not recommend for or against any medication, protocol or provider. Decisions about your health belong with a qualified professional who knows your history.

Ascendant Health is a coaching service. It does not practise medicine or prescribe.